Track Galmed Pharmaceuticals Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Galmed Pharmaceuticals Ltd. GLMD Open Galmed Pharmaceuticals Ltd. in new tab

0.5400 USD
EPS
-3.44
P/B
0.14
ROE
-46.34
Beta
0.42
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 20, 2026
EPS-3.44
Book Value3.49
Price to Book0.14
% Insiders0.994%
Estimates
Forward P/E-0.49
Forward EPS-1.03

DCF Valuation

Tweak assumptions to recompute fair value for Galmed Pharmaceuticals Ltd. (GLMD)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Galmed Pharmaceuticals Ltd. Logo Galmed Pharmaceuticals Ltd. Analysis (GLMD)

Israel Health Care Official Website Stock

Is Galmed Pharmaceuticals Ltd. a good investment? Galmed Pharmaceuticals Ltd. (GLMD) is currently trading at 0.5400 USD.

Earnings Schedule: Galmed Pharmaceuticals Ltd. is expected to release its next earnings report on May 20, 2026. The market consensus estimate for Forward EPS is -1.03.

Investor FAQ

Does Galmed Pharmaceuticals Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Galmed Pharmaceuticals Ltd.?

Galmed Pharmaceuticals Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 20, 2026. The company currently has a trailing EPS of -3.44.

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Exchange Ticker
NMS (United States) GLMD

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Aug. 30, 2024 0.080000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
May 15, 2023 0.070000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion